Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Retained Earnings: 2019-2024

Historic Retained Earnings for Eton Pharmaceuticals (ETON) over the last 6 years, with Dec 2024 value amounting to -$107.9 million.

  • Eton Pharmaceuticals' Retained Earnings fell 6.23% to -$114.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year decrease of 6.23%. This contributed to the annual value of -$107.9 million for FY2024, which is 3.67% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Retained Earnings of -$107.9 million as of FY2024, which was down 3.67% from -$104.1 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Retained Earnings registered a high of -$92.2 million during FY2020, and its lowest value of -$107.9 million during FY2024.
  • Over the past 3 years, Eton Pharmaceuticals' median Retained Earnings value was -$104.1 million (recorded in 2023), while the average stood at -$105.0 million.
  • Data for Eton Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 43.58% (in 2020) over the last 5 years.
  • Eton Pharmaceuticals' Retained Earnings (Yearly) stood at -$92.2 million in 2020, then dropped by 2.12% to -$94.1 million in 2021, then declined by 9.59% to -$103.1 million in 2022, then decreased by 0.91% to -$104.1 million in 2023, then declined by 3.67% to -$107.9 million in 2024.